Status:
COMPLETED
Levosimendan for Veno-arterial ECMO Weaning
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Cardiogenic Shock
Refractory Shock
Eligibility:
All Genders
18+ years
Brief Summary
Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a temporary mechanical circulatory support that has been increasingly used over the last decade to restore and maintain adequate end-orga...
Eligibility Criteria
Inclusion
- Age ≥18 years
- All consecutive patients admitted with VA-ECMO support for refractory cardiogenic shock
- All consecutive patients admitted for lobectomy or wedge video-assisted thoracoscopy
- Levosimendan administration was left to the discretion of the attending clinician
Exclusion
- Age \< 18 years
- VA-ECMO duration \< 48h
- VA-ECMO for refractory cardiac arrest
- Right heart or veno-venous ECMO
- VA-ECMO for circulatory failure following lung transplant surgery.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04323709
Start Date
January 1 2019
End Date
March 1 2020
Last Update
March 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Louis Pradel
Bron, France, 69500